Our differentiating capabilities to prosecute targets via covalency:
Proprietary Human “Reactome” Database Built on Translational Disease Models
Activity-Based Proteomic Probes and Proprietary Covalent Small Molecule Library
Versatile Chemoproteomics-Based Hit Finding Engine
Computational Platform for Rational Design and Optimization of Covalent Inhibitors
We have built an end-to-end platform for heterobifunctional degrader discovery which we are expanding to other chemically-induced proximity applications.
Designing Best-in-Class Small Molecules
Our computation-first approach is used to design molecules that rapidly reach the desired TPP for disease areas where effective therapeutic solutions are lacking.